tert-Butyl (2-methyl-7-azabicyclo[2.2.1]heptan-2-yl)carbamate

Catalog No. :
ACGLOW467
CAS No. :
2096992-25-3
Molecular Formula :
C12H22N2O2
Molecular Weight :
226.32

IUPAC Name:tert-butyl (2-methyl-7-azabicyclo[2.2.1]heptan-2-yl)carbamate

tert-Butyl (2-methyl-7-azabicyclo[2.2.1]heptan-2-yl)carbamate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%$1751.00Login to see priceIn stockInquiry
250mg97%$2800.00Login to see priceIn stockInquiry
500mg97%$4667.00Login to see priceInquiryInquiry
1g97%$6999.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl (2-methyl-7-azabicyclo[2.2.1]heptan-2-yl)carbamate
IUPAC Nametert-butyl (2-methyl-7-azabicyclo[2.2.1]heptan-2-yl)carbamate
MDL No.MFCD30532786
Molecular FormulaC12H22N2O2
Molecular Weight226.32
SMILESO=C(OC(C)(C)C)NC1(C)C(N2)CCC2C1
InChI KeyZWPWUBQASYMSSD-UHFFFAOYSA-N
Synonym2096992-25-3 | tert-butyl N-{2-methyl-7-azabicyclo[2.2.1]heptan-2-yl}carbamate | CS-D1490 | P21146 | tert-butyl (2-methyl-7-azabicyclo[2.2.1]heptan-2-yl)carbamate | tert-butylN-{2-methyl-7-azabicyclo[2.2.1]heptan-2-yl}carbamate | TERT-BUTYL N-{2-METHYL-7-
CAS No.2096992-25-3
PubChem CID126961393

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACGLOW467 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACGLOW467 route product structure diagram
    ACGLOW4672096992-25-3 In Stock
Inquiry

2. ACGLOW467 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACGLOW467 route product structure diagram
    ACGLOW4672096992-25-3 In Stock
Inquiry

Comments (0)